SAN

72.69

-0.86%↓

ARGX

685.6

-1.66%↓

SHL.DE

33.78

-0.03%↓

FRE

38.19

-3.95%↓

PHIA

21.8

-1.09%↓

SAN

72.69

-0.86%↓

ARGX

685.6

-1.66%↓

SHL.DE

33.78

-0.03%↓

FRE

38.19

-3.95%↓

PHIA

21.8

-1.09%↓

SAN

72.69

-0.86%↓

ARGX

685.6

-1.66%↓

SHL.DE

33.78

-0.03%↓

FRE

38.19

-3.95%↓

PHIA

21.8

-1.09%↓

SAN

72.69

-0.86%↓

ARGX

685.6

-1.66%↓

SHL.DE

33.78

-0.03%↓

FRE

38.19

-3.95%↓

PHIA

21.8

-1.09%↓

SAN

72.69

-0.86%↓

ARGX

685.6

-1.66%↓

SHL.DE

33.78

-0.03%↓

FRE

38.19

-3.95%↓

PHIA

21.8

-1.09%↓

Strona główna・Stock List・Laboratorios Farmaceuticos Rovi SA

Laboratorios Farmaceuticos Rovi SA

Closed

SectorHealthcare

59.5 -2.46

Buy Sell

Overview

Share price change

24h

Current

Min

59.5

Max

61.05

Key metrics
By Trading Economics
Income	-33M 9.5M
Sales	-66M 152M
P/E Sector Avg	26.292 51.415
EPS	0.834
Profit margin	6.216
Employees	1,950
EBITDA	-45M 18M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+36.25% upside

Dividends
By Dow Jones
Next Earnings	23 lip 2026

Market Stats
By TradingEconomics
Market Cap	-887M 3.2B
Previous open	61.96
Previous close	59.5

News Sentiment

By Acuity

50%

162 / 346 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Weak Bullish Evidence

51.1 / N/A Support & Resistance

Laboratorios Farmaceuticos Rovi SA Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

13 maj 2026, 22:54 UTC

Earnings

Xero Lifts Annual Earnings 18%, Flags More Growth Ahead

13 maj 2026, 23:51 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

13 maj 2026, 23:51 UTC

Market Talk

Australian Consumer Spending Is Holding Up; RBA Watching -- Market Talk

13 maj 2026, 23:45 UTC

Market Talk

Nikkei May Rise After Overnight U.S. Tech Gains -- Market Talk

13 maj 2026, 23:45 UTC

Market Talk

Global Equities Roundup: Market Talk

13 maj 2026, 23:17 UTC

Earnings

Samsung Fire & Marine Insurance 1Q Net Profit Beat FactSet-Compiled Consensus

13 maj 2026, 23:16 UTC

Earnings

Samsung Fire & Marine Insurance 1Q Net KRW635.22B Vs. Net KRW609.03B >000810.SE

13 maj 2026, 23:15 UTC

Earnings

Samsung Fire & Marine Insurance 1Q Oper Pft KRW861.13B Vs. Pft KRW792.36B >000810.SE

13 maj 2026, 23:14 UTC

Earnings

Samsung Fire & Marine Insurance 1Q Rev KRW6.676T Vs. KRW6.106T >000810.SE

13 maj 2026, 23:02 UTC

Market Talk

Earnings

Cisco Product Demand Climbing Even Without Hyperscalers -- Market Talk

13 maj 2026, 22:59 UTC

Market Talk

Earnings

Cisco Boosted by Tech Infrastructure Upgrade Cycle -- Market Talk

13 maj 2026, 22:24 UTC

Earnings

Xero FY U.S. Organic Revenue Growth 30%>XRO.AU

13 maj 2026, 22:23 UTC

Earnings

Xero FY International Organic Revenue Growth 25%>XRO.AU

13 maj 2026, 22:23 UTC

Earnings

Xero FY International Revenue Growth 47%>XRO.AU

13 maj 2026, 22:22 UTC

Earnings

Xero FY Australia, New Zealand Revenue Up 18% on Year >XRO.AU

13 maj 2026, 22:19 UTC

Earnings

Xero FY Australia, New Zealand Revenue Up 17% in Constant Currency>XRO.AU

13 maj 2026, 22:19 UTC

Earnings

Xero FY Net Customer Additions 506,000 Vs. 254,000>XRO.AU

13 maj 2026, 22:18 UTC

Earnings

Xero FY Rule of 40: 48.5% Vs. 44.3%>XRO.AU

13 maj 2026, 22:16 UTC

Earnings

Xero: Ebitda Guidance Includes NZD55M of Incremental U.S. Brand Spend>XRO.AU

13 maj 2026, 22:15 UTC

Earnings

Xero Expects FY27 Adjusted Ebitda of NZD860M-NZD920M>XRO.AU

13 maj 2026, 22:15 UTC

Earnings

Xero Expects FY27 Operating Revenue of NZD3.62B-NZD3.73B>XRO.AU

13 maj 2026, 22:13 UTC

Earnings

Xero FY Operating Expenses 70.5% of Operating Revenue Vs. 71.8%>XRO.AU

13 maj 2026, 22:12 UTC

Earnings

Xero FY Free Cash Flow NZD554.0M Vs. NZD506.7M>XRO.AU

13 maj 2026, 22:11 UTC

Earnings

Xero FY Adjusted Ebitda NZD757.4M Vs. NZD641.8M>XRO.AU

13 maj 2026, 22:11 UTC

Earnings

Xero FY Ebitda NZD789.5M Vs. NZD638.5M>XRO.AU

13 maj 2026, 22:10 UTC

Earnings

Xero Did Not Declare a Dividend>XRO.AU

13 maj 2026, 22:10 UTC

Earnings

Xero FY Rev NZD2.75B Vs. NZD2.10B >XRO.AU

13 maj 2026, 22:09 UTC

Earnings

Xero FY Net NZD167.4M Vs. Net NZD227.8M >XRO.AU

13 maj 2026, 22:00 UTC

Earnings

Cisco to Shed Jobs for All-In AI Push -- Update

13 maj 2026, 21:11 UTC

Earnings

Cisco Earnings and Revenue Beat Estimates on Strong AI Demand. Its Shares Surge. -- Barrons.com

Peer Comparison

Price change

Laboratorios Farmaceuticos Rovi SA Forecast

Price Target

By TipRanks

36.25% upside

12 Months Forecast

Average 83.25 EUR 36.25%

High 83.5 EUR

Low 83 EUR

Based on 2 Wall Street analysts offering 12 month price targets forLaboratorios Farmaceuticos Rovi SA - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

2 ratings

Buy

Hold

Sell

Based on 2 analysts giving stock ratings to Laboratorios Farmaceuticos Rovi SA - Dist in the past 3 months.

Technical Score

By Trading Central

51.1 / N/ASupport & Resistance

Recent bullish events outweigh bearish events.

Bearish events outweigh bullish events.

Sentiment

By Acuity

162 / 346 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Laboratorios Farmaceuticos Rovi SA

Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally. The company provides products for cardiology, osteoarticular/women's health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. Its principal products include Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa; and hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express, Fibrilin, and Sodium Heparin Rovi. It also provides contract-manufacturing services to other companies for a range of pharmaceutical forms, including prefilled syringes, vials, suppositories, tablets, and sachets. Laboratorios Farmaceuticos Rovi, S.A. was incorporated in 1946 and is headquartered in Madrid, Spain. Laboratorios Farmaceúticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.